Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Novo Nordisk Levemir To Launch Within Next 12 Months

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Long-acting insulin analogue clears FDA June 17 for treatment of type 1 and type 2 diabetes. Firm says approval makes it the only company in U.S. with a "full range" of short-acting and long-acting insulin analogues.

You may also be interested in...



Novo Nordisk Declares Levemir A Winner In U.S. Market

Sanofi-Aventis replacing Lilly as Novo's chief competitor in the diabetes market, company says.

Novo Nordisk Declares Levemir A Winner In U.S. Market

Sanofi-Aventis replacing Lilly as Novo's chief competitor in the diabetes market, company says.

Novo Nordisk Emphasizes Levemir “Predictability”

Planned second quarter launch would be nearly one year after FDA approval.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Recent And Upcoming FDA Advisory Committee Meetings

Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier

US FDA’s PDUFA VIII Ideas Could Include Creating Regulatory Science Research Program

Medicare Part B Inflation Rebate List Doubles For Third Quarter, Adds Several Amgen Drugs

See All
UsernamePublicRestriction

Register

PS062407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By